TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06500884: A Phase 2, Open-label, Randomized Study to Evaluate GPRC5D-related Oral Events

Sponsor: Janssen Research & Development, LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 210 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$9,979,200

Rescue Site Savings

+$6,606,600

Unlock Full NCT06500884 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06500884 Rescue Dossier →